Dr. Shubhamoy Gantait: FNB neurovascular intervention fellow at Mazumdar Shaw Medical centre, Narayana Health, India.

Article Details

Novelty

  • This study is among the first to correlate dual-energy CT quantitative parameters with IHC biomarkers in invasive breast cancer.

  • Introduces the concept of using DECT, traditionally for anatomical imaging, as a functional imaging tool reflecting tumor vascularity and biology.

  • Offers non-invasive insight into ER/PR/HER2 status, potentially reducing dependency on tissue biopsy in certain scenarios.

Impact

  • Can influence clinical decision-making by predicting tumor receptor status before biopsy results are available.

  • May help tailor neoadjuvant therapies more quickly, especially in aggressive or HER2-positive cancers.

  • Adds value to imaging studies by integrating anatomical and functional biomarkers in a single DECT scan.

Originality

  • Combines quantitative DECT parameters (IC, NIC, Zeff, slope K) with IHC biomarker analysis, which is not commonly reported in prior breast cancer studies.

  • Uses novel parameter slope K to correlate with tumor receptor expression.

  • Applies DECT as a dual diagnostic tool: staging and functional characterization.

Experimental Rigor

  • Prospective design increases reliability of results.

  • Multiple DECT parameters were systematically measured with region-of-interest (ROI) methodology, enhancing reproducibility.

  • Appropriate statistical methods (ROC curves, p-values) were applied.

  • Limitation: The study does not mention the sample size, which could affect statistical power.

Sustainability Impact

  • Offers a non-invasive imaging approach, potentially reducing repeat biopsies and associated medical waste.

  • Could decrease resource use in pathology labs if predictive imaging becomes reliable.

  • Enhances efficient patient workflow in oncology care settings, contributing indirectly to healthcare sustainability.

Applicability

  • Clinically applicable in breast cancer centers equipped with DECT scanners.

  • Can complement existing diagnostic protocols for ER/PR/HER2 status determination.

  • May guide personalized treatment decisions, especially in cases where biopsy is risky or delayed.

  • Potential for integration into AI-assisted imaging platforms for automated IHC prediction.

Research Portfolio

Dr. Shubhamoy Gantait is a highly skilled neurovascular interventionist and radiologist with advanced expertise in both diagnostic and interventional imaging. Currently serving as an FNB fellow at Mazumdar Shaw Medical Centre, Narayana Health, Bangalore, he specializes in stroke interventions, peripheral vascular procedures, and image-guided non-vascular interventions. With a strong foundation in neuroimaging, he combines clinical precision with research-driven approaches to improve patient outcomes.

Online Profile

ORCID Profile

Dr. Gantait maintains a professional presence across institutional and international platforms, reflecting his active engagement in the global radiology community. He is a member of prestigious organizations including the National Academy of Medical Sciences (MNAMS), Royal College of Radiology (RCR), Indian Society of Vascular Interventional Radiology (ISVIR), and Cardiovascular and Interventional Radiological Society of Europe (CIRSE). These affiliations underscore his commitment to advancing interventional radiology standards and sharing expertise across networks.

Education

Dr. Gantait earned his DM in Neuroimaging and Interventions from JIPMER, Puducherry, and completed a DNB in Radiodiagnosis from Rajiv Gandhi Cancer Institute, New Delhi. He graduated with an MBBS degree from Calcutta National Medical College, achieving honors in pediatrics and preventive & social medicine. His ongoing FNB fellowship in Neurovascular Interventions at Mazumdar Shaw Medical Centre further strengthens his super-specialty knowledge and procedural expertise in complex cerebrovascular and peripheral interventions.

Research Focus

His research primarily focuses on advanced neuroimaging techniques and image-guided interventions aimed at improving diagnostic accuracy and therapeutic outcomes. Dr. Gantait has investigated the role of ASL perfusion MRI in acute encephalopathy and diffusion-weighted MRI in prostate cancer evaluation, demonstrating a commitment to integrating imaging biomarkers into clinical decision-making. His work bridges diagnostic radiology and interventional strategies, contributing to innovations in stroke and vascular care.

Experience

Dr. Gantait has a diverse clinical background, having worked in top-tier medical institutions including JIPMER, Rajiv Gandhi Cancer Institute, BP Poddar Hospital, and Welkin Medicare. He has extensive experience in CT, MRI, ultrasound, and fluoroscopic procedures, and is proficient in advanced neurovascular interventions, peripheral vascular embolizations, biliary procedures, and sclerotherapy of vascular malformations. His roles have ranged from senior resident and consultant radiologist to interventional fellow, demonstrating a blend of academic rigor and hands-on expertise.

Research Timeline & Activities

Dr. Gantait began his research journey during his DNB residency (2015–2018), focusing on diffusion-weighted MRI in oncology. During his DM training (2021–2023), he conducted studies on ASL perfusion MRI in acute neurological disorders, developing clinical protocols for neurovascular assessment. Currently, as an FNB fellow, he participates in multicenter clinical trials, protocol development for stroke interventions, and advanced imaging studies, actively contributing to research in neurovascular and peripheral interventions.

Awards & Honors

He has been recognized with multiple accolades for academic excellence and clinical proficiency, including the Best DNB Resident Award (2017), gold medal in pediatrics during MBBS, 1st rank in FET 2023 in Neurovascular Intervention, and 3rd rank in JIPMER DM/MCh entrance (2021). Early academic achievements include a state-level merit ranking in Class 10 and MBBS honors in preventive medicine and pediatrics, reflecting a consistent record of excellence.

Strength an Emerging Researcher Award 

1. Early-Career Status

Requirement: Typically researchers with under 5–7 years of post-doctoral or equivalent experience.

Assessment: Dr. Gantait completed his DNB (2018) and DM (2023) and is currently pursuing an FNB fellowship. His active post-specialty research career spans roughly 3–5 years.

Verdict:  Meets the early-career criterion.

2. Research Innovation & Originality

Evidence:

First studies correlating dual-energy CT quantitative parameters with IHC biomarkers in breast cancer, integrating anatomical and functional imaging.

Novel use of slope K parameter for predicting tumor receptor expression.

Pioneering research in ASL perfusion MRI for acute encephalopathy and diffusion-weighted MRI in oncology.

Impact: Introduces non-invasive predictive imaging approaches with clinical decision-making potential.

Verdict:  Strong innovation and originality.

3. Research Impact & Applicability

Evidence:

DECT study offers potential to reduce biopsy dependency, accelerate neoadjuvant therapy decisions, and enhance imaging efficiency.

Work on neuroimaging (stroke, peripheral vascular interventions) demonstrates translational value for patient care.

Publications in reputed journals and involvement in multicenter clinical trials.

Verdict:  High translational and clinical impact.

4. Academic & Professional Recognition

Evidence:

Membership in MNAMS, RCR, ISVIR, CIRSE, reflecting international recognition.

Multiple awards: Best DNB Resident, Gold Medal in MBBS Pediatrics, 1st rank FET 2023, 3rd rank JIPMER DM/MCh entrance.

Verdict: Recognized by peers and professional bodies; strong leadership potential.

5. Sustained Research Trajectory

Evidence:

Continuous research from DNB residency (2015–2018) → DM (2021–2023) → current FNB fellowship.

Active in clinical trials, imaging protocol development, and interdisciplinary collaborations.

Demonstrates a trajectory from foundational MRI research to innovative DECT imaging in oncology.

Verdict: Demonstrates a strong, sustained and evolving research trajectory.

Shubhamoy Gantait, Medicine, Emerging Researcher Award